Navigation Links
QRxPharma Releases Successful Phase 3 Study Results for 'Dual Opioid' Pain Therapy
Date:5/5/2008

Q8003IR Met Primary Endpoints; Demonstrated Strong Reduction of Pain Intensity

SYDNEY, Australia and BEDMINSTER, N.J., May 5

/PRNewswire-FirstCall/ -- QRxPharma Limited (ASX: QRX), a clinical-stage specialty pharmaceutical company focused on the development and commercialisation of therapies for pain and central nervous system (CNS) disorders, announced today initial Phase 3 efficacy results for Q8003IR, an immediate release dual-opioid product intended for the acute management of moderate to severe pain.

"Initial Phase 3 efficacy data demonstrated statistically significant analgesic activity at all doses tested and reinforces the potential clinical benefit and commercial value of QRxPharma's lead dual-opioid product," said Dr. John Holaday, Managing Director and Chief Executive Officer, QRxPharma. "We are pleased with this study outcome and believe that it demonstrates that the Company remains on target to complete clinical testing for Q8003IR, submit a New Drug Application (NDA) in 2009 and achieve its goal of product launch in 2010."

The double-blind, placebo-controlled study was designed to compare the efficacy and safety of four different dosage regimens of Q8003IR, a fixed ratio morphine/oxycodone combination. 256 patients with moderate to severe pain following surgery (bunionectomy) completed the trial, and it was conducted at six US clinical research sites. The primary efficacy analysis compared the change in pain intensity scores over the 48 hr dosing period (SPID48) in patients receiving Q8003IR vs. placebo.

Among all patients receiving Q8003IR, approximately 50% reported good to excellent global improvement (vs. 13% for placebo) and demonstrated a strong dose-response effect (p<0.001) in reducing pain intensity scores [i.e. the sum of pain intensity difference over 48 hours relative to the first dose (SPID48)] and other measures of analgesic effect. Per treatment group, median doses received every 4 hours
'/>"/>

SOURCE QRxPharma
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. QRxPharma Doses First Patients in Phase III Clinical Trial Program for its Dual Opioid Pain Therapy
2. Immunosyn Releases Wound Healing Photographs From the First Phase Proof of Concept Trial in Europe for Treatment of Diabetic Ulcers With Biopharmeceutical SF-1019
3. TCS Healthcare Technologies Releases Three New Clinical Care Programs Within ACUITY
4. Immunosyn Corporation Releases SF-1019 Study Results
5. Cardinal Health Releases New Tool to Combat MRSA Infections in Hospitals
6. AcroMetrix Releases New OptiQuant(R) HIV-1 Quantification Panel
7. CEL-SCI Corporation Releases Letter to Shareholders
8. Sarasotas Roskamp Institute Releases Study Defining a Mechanism for Development of Obesity and the Metabolic Syndrome, Forerunners of Type 2 Diabetes
9. Data Show Preoperative Assessment of Breast Cancer Patients Enables Early Diagnosis, Successful Treatment of Lymphedema
10. Novagali Pharma Successfully Enrolls First Patient in U.S. Phase I Clinical Study with CORTIJECT(R) for Diabetic Macular Edema
11. Nostrum Announces the Successful Completion of Early Proof-of-Concept Study for its Novel Clot Busting Therapeutic Protein
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... , Jan. 23, 2015  Immune Therapeutics, Inc. today announced the ... the compounding, packaging and distributing of its naltrexone tablets.  The ... United States . KRS Global is ... tablets in various strengths for individual patients in response to ...
(Date:1/23/2015)... Jan. 23, 2015  iMD Companies, Inc. (ICBU) has repositioned itself ... share and grab a foothold in the hydroponic, hemp and ... and a presence in the sector, and recently partnering with ... of hemp and medical marijuana, iMD is committing to bring ...
(Date:1/23/2015)... DUBLIN , Jan. 23, 2015  Mallinckrodt plc (NYSE: ... of Directors has approved a share repurchase program. The ... $300 million of Mallinckrodt plc ordinary shares. ... opportunities remain top priorities as we continue to pursue ...
Breaking Medicine Technology:Immune Therapeutics, Inc. Announces Agreement with KRS Global Biotechnology, Inc. 2Immune Therapeutics, Inc. Announces Agreement with KRS Global Biotechnology, Inc. 3Immune Therapeutics, Inc. Announces Agreement with KRS Global Biotechnology, Inc. 4iMD Companies Poised to Make Impact in Multi-Billion Dollar Medical Marijuana Sector With Recent Investments and Strategic Partnerships 2Mallinckrodt plc Announces Share Repurchase Program 2Mallinckrodt plc Announces Share Repurchase Program 3Mallinckrodt plc Announces Share Repurchase Program 4
(Date:1/22/2015)... 22, 2015 The federal court overseeing thousands ... District Court, Southern District of West Virginia has upheld a ... proceeding’s first bellwether trial. In an Order dated January 21st, ... after finding that C.R. Bard had not proven a miscarriage ...
(Date:1/22/2015)... Autocarinsurancebest.com has released a new blog post explaining the main ... , Auto insurance quotes help many drivers find the ... to call an agent or visit an agency for price ... website: http://autocarinsurancebest.com/ . , Every business who relies heavily ...
(Date:1/22/2015)... 2015 A study recently published ... journal Medicine & Science in Sports & Exercise ... help reduce gastrointestinal (GI) problems associated with physical ... in the double-blind, placebo-controlled study took 10 grams ...
(Date:1/22/2015)... January 22, 2015 Four years since the release ... which coincided with the marriage of Avasa & Matthew Love – ... which is scheduled for release through White Swan Records on February ... there is a sacred path available to all of us to ...
(Date:1/22/2015)... a famous dress online store for wedding dresses and other ... of wedding dresses , and launches a site-wide women’s dress ... on your big day; the wedding gown is the most ... find the most suitable wedding dress. Now, we are proud ...
Breaking Medicine News(10 mins):Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 2Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 3Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 4Health News:Commercial Auto Insurance Provides Several Important Features! 2Health News:Study Shows Kyowa Hakko’s L-Citrulline May Help Reduce Gastrointestinal Injury During Strenuous Exercise 2Health News:Study Shows Kyowa Hakko’s L-Citrulline May Help Reduce Gastrointestinal Injury During Strenuous Exercise 3Health News:THE ROAD by Avasa & Matthew Love -- A New Album 2Health News:THE ROAD by Avasa & Matthew Love -- A New Album 3Health News:THE ROAD by Avasa & Matthew Love -- A New Album 4Health News:Find The Most Suitable Wedding Dress At JJsHouse.com 2
... ... largest production/post-production company in the Mid-Atlantic region, acquires premiere Blu-ray encoding equipment in ... Geographic Films, Discovery Networks and various documentary filmmakers. , ... (PRWEB) June 26, 2010 -- ...
... Katie ... with Polycystic Ovarian Syndrome how they can lose weight and achieve hormonal balance naturally. ... (PRWEB) ... Katie Humphrey,s three proven steps to lose weight and naturally balance hormonal levels in ...
... New sublative approach ... Dr. David J. Goldberg. , ... (PRWEB) June 25, 2010 -- Dr. David J. Goldberg, a leading dermatologist and Director ... the practice will be offering the new eMatrix ™ treatment for acne scarring in ...
... ... , ... 25, 2010 -- AthletiCo Physical and Occupational Therapy , an Illinois and Milwaukee-based provider ... reuse, and recycle. Phones 4 Charity is a national program designed to ...
... the Intrepid Fallen Heroes Fund on June 24 officially dedicated ... facility in Bethesda, Md., dedicated to researching, diagnosing and treating ... David Hovda, director of the UCLA Brain Injury Research Center ... major role in helping to frame the creation of the ...
... Dennis Thompson HealthDay Reporter , FRIDAY, June ... medicine cabinets and bathroom drawers: a prescription vial containing ... past its sell-by date. But unless they,re spring-cleaning, ... when they do, people often turn to the toilet ...
Cached Medicine News:Health News:Henninger Media Services Now Offers Hollywood-Quality Blu-ray Products 2Health News:Henninger Media Services Now Offers Hollywood-Quality Blu-ray Products 3Health News:Upcoming Simulcast to Teach Women How to Lose Weight and Naturally Balance Hormones with Polycystic Ovarian Syndrome 2Health News:Skin Laser and Surgery Specialists Offers New eMatrix&#8482; Treatment for Acne Scarring 2Health News:Skin Laser and Surgery Specialists Offers New eMatrix&#8482; Treatment for Acne Scarring 3Health News:AthletiCo Physical Therapy Holds July Cell Phone Drive 2Health News:UCLA researchers, US military collaborate to open center for traumatic brain injury 2Health News:Outdated Meds Pose Problems If Kept or Tossed 2Health News:Outdated Meds Pose Problems If Kept or Tossed 3
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: